相关实验视频
Updated: Jul 11, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
900
用于治疗创伤诱导的凝血病的前热血素复合缩剂 (PCC):系统性审查和元分析
Ioannis Hannadjas1, Arthur James2,3, Ross Davenport1
1Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London, England.
Critical care (London, England)
|November 3, 2023
概括
血栓复合缩剂 (PCC) 在创伤患者中没有显著降低死亡率或增加静脉血栓栓塞 (VTE) 风险. 需要进一步的研究才能充分理解PCC.
科学领域:
- 创伤和紧急医疗医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 创伤诱导的凝血病 (TIC) 是患有重大出血的患者经常出现的并发症.
- 血栓复合缩剂 (PCC) 是一种潜在的治疗剂,用于纠正TIC,但其有效性和最佳使用仍然不确定.
研究的目的:
- 系统地评估前热血素复合物缩剂 (PCC) 在治疗创伤诱导凝血病 (TIC) 的成年患者严重出血的疗效和安全性.
- 评估PCC对住院死亡率和静脉血栓塞栓症 (VTE) 风险的影响.
主要方法:
- 在MEDLINE和EMBASE上进行了系统的文献搜索,并通过clinicaltrials.gov补充了正在进行的研究.
- 包括的研究集中在接受PCC治疗TIC的成年创伤患者上;排除的是儿科病例,仅创伤性脑损伤研究和仅接受抗凝剂的患者.
- 使用随机效应模型进行了元分析,以汇集有关死亡率和VTE的数据,评估了偏差风险和证据质量.
主要成果:
- 纳入了10项研究 (9项观察性,1项RCT) 涉及1150名患者;大多数使用的是20-30U/Kg的4因子PCC.
- 对观察性研究的综合分析显示,死亡率 (OR 0.97) 或深静脉血栓 (DVT) (OR 0.83) 没有显著差异.
- 对所有纳入研究的综合分析也没有发现死亡率有显著降低 (OR 0.94) 或DVT增加 (OR 1.00).
结论:
- 目前的证据表明,前列红素复合缩剂 (PCC) 不显著降低死亡率或增加静脉血栓栓塞 (VTE) 的风险在创伤患者出血.
- 血栓事件的可能性需要在正在进行的随机对照试验 (RCT) 中进一步调查,旨在澄清PCC的安全性和有效性.
相关概念视频
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Coagulation
6.9K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.9K
Extrinsic and Intrinsic Pathways of Hemostasis
8.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Introduction to Hemostasis
8.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.1K
Clot Retraction and Fibrinolysis
6.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.2K

